No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplant 2023 Dec;58(12):1390-1393
Date
09/05/2023Pubmed ID
37666957Pubmed Central ID
PMC11221560DOI
10.1038/s41409-023-02092-3Scopus ID
2-s2.0-85169665242 (requires institutional sign-in at Scopus site)Author List
Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, Auletta JJ, Kent M, Hashem H, Talano JA, Rotz SJ, Fraint E, Myers KC, Leung W, Sharma A, Bhatt NS, Driscoll TA, Yu LC, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GAAuthors
Kwang Woo Ahn PhD Director, Professor in the Data Science Institute department at Medical College of WisconsinLarisa Broglie MD, MS Associate Professor in the Pediatrics department at Medical College of Wisconsin
Mary Eapen MBBS, DCh, MRCPI, MS Professor in the Medicine department at Medical College of Wisconsin
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antigens, CD34Child
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Humans
Neuroblastoma
Peripheral Blood Stem Cell Transplantation
Transplantation, Autologous